JP2010511059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511059A5 JP2010511059A5 JP2009539434A JP2009539434A JP2010511059A5 JP 2010511059 A5 JP2010511059 A5 JP 2010511059A5 JP 2009539434 A JP2009539434 A JP 2009539434A JP 2009539434 A JP2009539434 A JP 2009539434A JP 2010511059 A5 JP2010511059 A5 JP 2010511059A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- substituted
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 65
- 125000000753 cycloalkyl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 or het Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 238000011254 conventional chemotherapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000005228 aryl sulfonate group Chemical class 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- TXHPORRYUKITDP-UHFFFAOYSA-N sulfamoylsulfamic acid Chemical compound NS(=O)(=O)NS(O)(=O)=O TXHPORRYUKITDP-UHFFFAOYSA-N 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- 241000288906 Primates Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86744806P | 2006-11-28 | 2006-11-28 | |
| US60/867,448 | 2006-11-28 | ||
| US89108807P | 2007-02-22 | 2007-02-22 | |
| US60/891,088 | 2007-02-22 | ||
| PCT/US2007/085579 WO2008067280A2 (en) | 2006-11-28 | 2007-11-27 | Combination of iap inhibitors and flt3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010511059A JP2010511059A (ja) | 2010-04-08 |
| JP2010511059A5 true JP2010511059A5 (cg-RX-API-DMAC10.html) | 2011-01-20 |
| JP5394249B2 JP5394249B2 (ja) | 2014-01-22 |
Family
ID=39386468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539434A Expired - Fee Related JP5394249B2 (ja) | 2006-11-28 | 2007-11-27 | Ｉａｐ阻害剤とｆｌｔ３阻害剤の組合せ剤 |
Country Status (20)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| EP2296650B1 (en) | 2008-05-16 | 2020-05-06 | Novartis AG | Immunomodulation by iap inhibitors |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ）） |
| KR20160030099A (ko) | 2013-06-25 | 2016-03-16 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| EP3928780A4 (en) | 2019-02-22 | 2022-12-07 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1453661A1 (ru) * | 1972-11-17 | 1989-10-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Противоопухолевое средство "продимин |
| CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| PL2253614T3 (pl) * | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| US20090005411A1 (en) | 2005-12-20 | 2009-01-01 | Novartic Ag | Combinations of Organic Compounds |
| PE20110217A1 (es) * | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
-
2007
- 2007-11-27 KR KR1020097013350A patent/KR20090087094A/ko not_active Abandoned
- 2007-11-27 PL PL07868853T patent/PL2089024T3/pl unknown
- 2007-11-27 MX MX2009005621A patent/MX2009005621A/es active IP Right Grant
- 2007-11-27 AU AU2007325280A patent/AU2007325280B2/en not_active Ceased
- 2007-11-27 CA CA002670498A patent/CA2670498A1/en not_active Abandoned
- 2007-11-27 AT AT07868853T patent/ATE509629T1/de active
- 2007-11-27 BR BRPI0719543-5A patent/BRPI0719543A2/pt not_active IP Right Cessation
- 2007-11-27 US US12/516,062 patent/US8492429B2/en not_active Expired - Fee Related
- 2007-11-27 RU RU2009124590/15A patent/RU2456983C2/ru not_active IP Right Cessation
- 2007-11-27 EP EP07868853A patent/EP2089024B1/en active Active
- 2007-11-27 JP JP2009539434A patent/JP5394249B2/ja not_active Expired - Fee Related
- 2007-11-27 PT PT07868853T patent/PT2089024E/pt unknown
- 2007-11-27 WO PCT/US2007/085579 patent/WO2008067280A2/en not_active Ceased
-
2009
- 2009-05-04 IL IL198551A patent/IL198551A0/en unknown
- 2009-05-22 TN TNP2009000206A patent/TN2009000206A1/fr unknown
- 2009-05-27 GT GT200900142A patent/GT200900142A/es unknown
- 2009-06-03 MA MA31946A patent/MA30966B1/fr unknown
- 2009-06-24 NO NO20092417A patent/NO20092417L/no not_active Application Discontinuation
- 2009-06-25 CO CO09066298A patent/CO6210722A2/es not_active Application Discontinuation
- 2009-06-26 EC EC2009009472A patent/ECSP099472A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7600396B2 (ja) | 化合物及びその使用 | |
| ES2402791T3 (es) | Forma cristalina de la sal diclorhidrato de ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1H-imidazol-5-il)-4-bifenilil)-1H-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
| JP6905053B2 (ja) | ベンジルフェニルエーテル誘導体、その調製方法、並びにその医薬組成物及び使用 | |
| CN118591540A (zh) | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 | |
| EP4097096A2 (en) | Compounds and uses thereof | |
| CA3254823A1 (en) | HETEROCYCLIC COMPOUNDS USEFUL FOR MODULATING BAF COMPLEXES | |
| UA130198C2 (uk) | Сполуки 4-оксо-3,4-дигідрохіназолінону для лікування braf-асоційованих захворювань та розладів | |
| EP4132529A1 (en) | Compounds and uses thereof | |
| ES2899852T3 (es) | Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico | |
| RU2009118487A (ru) | Органические соединения | |
| EA011720B1 (ru) | ПРОИЗВОДНЫЕ β-D-НУКЛЕОЗИДА И ИХ ПРИМЕНЕНИЕ | |
| CA2535242A1 (en) | Use of c-kit inhibitors for treating type ii diabetes | |
| US9701711B2 (en) | Modulators of protease activated receptors | |
| JP2010511059A (ja) | Ｉａｐ阻害剤とｆｌｔ３阻害剤の組合せ剤 | |
| HUT74453A (en) | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkane-carboxylic acid derivatives, process for preparing them, their intermediates, use and pharmaceutical compns. contg. the said compds. | |
| KR20090083412A (ko) | 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도 | |
| AU2017255525A1 (en) | 6-aminopyridin-3-yl thiazoles as modulators of rorgammat | |
| CA3152168A1 (en) | Cannabinoid prodrug compounds | |
| JPWO2019022223A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
| WO2011057220A2 (en) | Compositions and methods for treating lymphoma | |
| BR112020001588A2 (pt) | agente terapêutico ou um agente preventivo para alopecia areata | |
| KR101278011B1 (ko) | 만성 폐쇄성 폐질환 치료제 | |
| ES2755740T3 (es) | Monohidrato de (S)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxi-fenil)-1H-pirazol-3-ilamino)pirazin-2-carbonitrilo | |
| WO2019074895A1 (en) | COMPOUNDS FOR INHIBITING SECRETORY LEUKOCYTE PROTEIN INHIBITOR (SLPI) | |
| KR20180134401A (ko) | 예를 들어 알츠하이머병을 치료하기 위한 선택적 BACE1 억제제로서 N-[3-[2-아미노-5-(1,1-디플루오로에틸)-4,4a,5,7-테트라히드로푸로[3,4-d][1,3]옥사진-7a-일]-4-플루오로-페닐]-5-(트리플루오로메틸)피리딘-2-카르복스아미드 및 그의 (4aR,5S,7aS) 이성질체 |